Spruce Street Capital LP
13F Reported Value
ⓘ$509.7M
Holdings
30
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Spruce Street Capital LP disclosed 30 positions worth $509.7M in its Form 13F-HR for Q2 2026, led by $KNSA (Kiniksa Pharmaceuticals International, plc) at 11.5% of the equity portfolio, followed by $RLAY and $LBRX. During the quarter the fund opened 5 new positions and exited 3 — including a new stake in $IFRX and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (97.5% of disclosed assets). All figures are sourced directly from Spruce Street Capital LP’s Form 13F-HR filing with the SEC under CIK 2050194.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $58.7M918,070 sh
- 19.5#2,792
Quality
$55.8M2,984,125 sh - —
Quality
$44.7M1,376,159 sh - —
Quality
$44.2M6,391,328 sh - —
Quality
$35.7M1,353,047 sh - 22.6
Quality
$34.6M354,816 sh - —
Quality
$28.5M543,876 sh - —
Quality
$21.3M3,452,576 sh - —
Quality
$17.8M306,047 sh - —
Quality
$16.7M329,006 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Kiniksa Pharmaceuticals International, plc$KNSA | — | $58.7M | 918,070 |
 Relay Therapeutics, Inc.$RLAY | 19.5#2,792 | $55.8M | 2,984,125 |
 LB PHARMACEUTICALS INC$LBRX | — | $44.7M | 1,376,159 |
 RELMADA THERAPEUTICS, INC.$RLMD | — | $44.2M | 6,391,328 |
 Alto Neuroscience, Inc.$ANRO | — | $35.7M | 1,353,047 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 22.6 | $34.6M | 354,816 |
 Alkermes plc.$ALKS | — | $28.5M | 543,876 |
 Savara Inc$SVRA | — | $21.3M | 3,452,576 |
 Vaxcyte, Inc.$PCVX | — | $17.8M | 306,047 |
 Enliven Therapeutics, Inc.$ELVN | — | $16.7M | 329,006 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Spruce Street Capital LP's 30 positions.
Showing top 10 of 30 holdings.
Sector Allocation
Healthcare
$497.2M
Financials
$7.2M
Other
$5.3M
Full Holdings — Spruce Street Capital LP (Q2 2026)
All 30 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $KNSA | Kiniksa Pharmaceuticals International, plc | $58.7M | 11.5% | +21% | — |
| 2 | $RLAY | Relay Therapeutics, Inc. | $55.8M | 10.9% | +0% | 19.5 |
| 3 | $LBRX | LB PHARMACEUTICALS INC | $44.7M | 8.8% | +0% | — |
| 4 | $RLMD | RELMADA THERAPEUTICS, INC. | $44.2M | 8.7% | +2% | — |
| 5 | $ANRO | Alto Neuroscience, Inc. | $35.7M | 7.0% | +2% | — |
| 6 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $34.6M | 6.8% | -5% | 22.6 |
| 7 | $ALKS | Alkermes plc. | $28.5M | 5.6% | +71% | — |
| 8 | $SVRA | Savara Inc | $21.3M | 4.2% | +2% | — |
| 9 | $PCVX | Vaxcyte, Inc. | $17.8M | 3.5% | +25% | — |
| 10 | $ELVN | Enliven Therapeutics, Inc. | $16.7M | 3.3% | +0% | — |
| 11 |  $ENTA | ENANTA PHARMACEUTICALS INC | $15.9M | 3.1% | +17% | 17.8 |
| 12 |  $CATX | Perspective Therapeutics, Inc. | $12.6M | 2.5% | +41% | — |
| 13 |  $IFRX | InflaRx N.V. | $12.0M | 2.4% | NEW | — |
| 14 |  $SRZN | Surrozen, Inc./DE | $11.2M | 2.2% | +0% | — |
| 15 |  $ALMS | ALUMIS INC. | $11.0M | 2.2% | +0% | 7.1 |
| 16 |  $IPSC | Century Therapeutics, Inc. | $9.9M | 1.9% | +0% | 33.5 |
| 17 |  $NERV | Minerva Neurosciences, Inc. | $9.2M | 1.8% | +0% | — |
| 18 |  $SABS | SAB Biotherapeutics, Inc. | $8.6M | 1.7% | +0% | — |
| 19 |  $ANTX | AN2 Therapeutics, Inc. | $8.0M | 1.6% | +0% | — |
| 20 |  $ERAS | Erasca, Inc. | $7.7M | 1.5% | +0% | — |
| 21 |  $IKT | Inhibikase Therapeutics, Inc. | $7.3M | 1.4% | +0% | — |
| 22 |  $RACC | Research Alliance Corp III | $5.3M | 1.1% | NEW | — |
| 23 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $5.3M | 1.0% | +0% | — |
| 24 |  $ZLAB | Zai Lab Ltd | $5.3M | 1.0% | NEW | — |
| 25 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $4.8M | 0.9% | NEW | — |
| 26 |  $LXEO | Lexeo Therapeutics, Inc. | $4.3M | 0.8% | +0% | — |
| 27 |  $ALEC | Alector, Inc. | $4.2M | 0.8% | +0% | 10.9 |
| 28 |  $LONA | LeonaBio, Inc. | $3.6M | 0.7% | +0% | — |
| 29 |  $CRVS | Corvus Pharmaceuticals, Inc. | $3.5M | 0.7% | +0% | — |
| 30 |  $JATT | JATT II Acquisition Corp. | $1.8M | 0.4% | NEW | — |
New Positions (5)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Spruce Street Capital LP including:
Track Spruce Street Capital LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Spruce Street Capital LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Spruce Street Capital LP
13F Pro is an AI hedge fund tracker and stock research platform. For Spruce Street Capital LP (SEC CIK: 2050194), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Spruce Street Capital LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.